{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:13:49Z","timestamp":1788506029942,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82400204"],"award-info":[{"award-number":["82400204"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82500198"],"award-info":[{"award-number":["82500198"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Research and Development Program of China","award":["2023YFA1800103"],"award-info":[{"award-number":["2023YFA1800103"]}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["2024A03J1022"],"award-info":[{"award-number":["2024A03J1022"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A15115110992"],"award-info":[{"award-number":["2023A15115110992"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025A1515010062"],"award-info":[{"award-number":["2025A1515010062"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (FLT3-ITD) is a well-characterized genetic alteration associated with poor prognosis in acute myeloid leukemia (AML). Although FLT3 inhibitors, such as gilteritinib and quizartinib, initially show clinical efficacy, resistance frequently emerges because of secondary mutations. Through a kinase inhibitor library screen, we identified XL999, which exhibits potent antileukemic activity across diverse FLT3-mutant AML cell lines and primary patient samples. Mechanistically, biochemical and molecular docking analyses revealed that XL999 directly binds to FLT3-ITD, potentially independent of the common F691 resistance site, thereby suppressing downstream signaling pathways to induce cell cycle arrest and apoptosis. In preclinical mouse models harboring refractory FLT3-ITD-D835Y or ITD-F691L mutations, oral administration of XL999 effectively reduced the leukemic burden across the peripheral blood, spleen, and bone marrow, significantly prolonging survival compared with gilteritinib and quizartinib, with no overt systemic toxicity observed in short-term mouse tolerability studies. Furthermore, XL999 demonstrated robust efficacy in patient-derived xenograft models, complemented by a favorable oral bioavailability profile. Together, these findings suggest that XL999 may represent an orally bioavailable FLT3 inhibitor with the potential to overcome clinically relevant secondary resistance mutations in FLT3-ITD-positive AML, supporting its further investigation as a therapeutic candidate.<\/jats:p>","DOI":"10.1186\/s43556-026-00561-x","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:43:31Z","timestamp":1788504211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The type I FLT3 inhibitor XL999 overrides secondary FLT3-ITD mutations that arise under gilteritinib and quizartinib treatment in acute myeloid leukemia"],"prefix":"10.1186","volume":"7","author":[{"given":"Shiyang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvyin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6899-8765","authenticated-orcid":false,"given":"Peihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"1","key":"561_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01168-8","volume":"7","author":"Y Yang","year":"2022","unstructured":"Yang Y, Li S, Wang Y, Zhao Y, Li Q. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduct Target Ther. 2022;7(1):329. https:\/\/doi.org\/10.1038\/s41392-022-01168-8.","journal-title":"Signal Transduct Target Ther"},{"issue":"23","key":"561_CR2","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/nejmoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321. https:\/\/doi.org\/10.1056\/nejmoa1516192.","journal-title":"N Engl J Med"},{"issue":"22","key":"561_CR3","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/nejmoa1301689","volume":"368","author":"N Cancer Genome Atlas Research","year":"2013","unstructured":"Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059\u201374. https:\/\/doi.org\/10.1056\/nejmoa1301689.","journal-title":"N Engl J Med"},{"issue":"17","key":"561_CR4","doi-asserted-by":"publisher","first-page":"4074","DOI":"10.1182\/blood-2007-11-125476","volume":"113","author":"F Breitenbuecher","year":"2009","unstructured":"Breitenbuecher F, Schnittger S, Grundler R, Markova B, Carius B, Brecht A, et al. Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood. 2009;113(17):4074\u20137. https:\/\/doi.org\/10.1182\/blood-2007-11-125476.","journal-title":"Blood"},{"issue":"12","key":"561_CR5","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2009-03-209999","volume":"114","author":"S Kayser","year":"2009","unstructured":"Kayser S, Schlenk RF, Londono MC, Breitenbuecher F, Wittke K, Du J, et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood. 2009;114(12):2386\u201392. https:\/\/doi.org\/10.1182\/blood-2009-03-209999.","journal-title":"Blood"},{"issue":"5","key":"561_CR6","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","volume":"111","author":"RE Gale","year":"2008","unstructured":"Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776\u201384. https:\/\/doi.org\/10.1182\/blood-2007-08-109090.","journal-title":"Blood"},{"issue":"4","key":"561_CR7","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1182\/blood-2006-04-015826","volume":"110","author":"AJ Mead","year":"2007","unstructured":"Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood. 2007;110(4):1262\u201370. https:\/\/doi.org\/10.1182\/blood-2006-04-015826.","journal-title":"Blood"},{"issue":"2","key":"561_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299\u2013312. https:\/\/doi.org\/10.1038\/s41375-018-0357-9.","journal-title":"Leukemia"},{"issue":"16","key":"561_CR9","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/sj.onc.1205332","volume":"21","author":"H Kiyoi","year":"2002","unstructured":"Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene. 2002;21(16):2555\u201363. https:\/\/doi.org\/10.1038\/sj.onc.1205332.","journal-title":"Oncogene"},{"issue":"3","key":"561_CR10","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","volume":"99","author":"JU Kazi","year":"2019","unstructured":"Kazi JU, Ronnstrand L. FMS-like tyrosine kinase 3\/FLT3: from basic science to clinical implications. Physiol Rev. 2019;99(3):1433\u201366. https:\/\/doi.org\/10.1152\/physrev.00029.2018.","journal-title":"Physiol Rev"},{"key":"561_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.pharmthera.2018.06.016","volume":"191","author":"LR Klug","year":"2018","unstructured":"Klug LR, Kent JD, Heinrich MC. Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases. Pharmacol Ther. 2018;191:123\u201334. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.06.016.","journal-title":"Pharmacol Ther"},{"key":"561_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-4-13","volume":"4","author":"S Takahashi","year":"2011","unstructured":"Takahashi S. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J Hematol Oncol. 2011;4:13. https:\/\/doi.org\/10.1186\/1756-8722-4-13.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"561_CR13","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","volume":"100","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532\u201342. https:\/\/doi.org\/10.1182\/blood-2002-02-0492.","journal-title":"Blood"},{"issue":"1","key":"561_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2004-07-2942","volume":"106","author":"C Choudhary","year":"2005","unstructured":"Choudhary C, Schwable J, Brandts C, Tickenbrock L, Sargin B, Kindler T, et al. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood. 2005;106(1):265\u201373. https:\/\/doi.org\/10.1182\/blood-2004-07-2942.","journal-title":"Blood"},{"issue":"1","key":"561_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-018-0675-4","volume":"11","author":"M Wu","year":"2018","unstructured":"Wu M, Li C, Zhu X. FLT3 inhibitors in acute myeloid leukemia. J Hematol Oncol. 2018;11(1):133. https:\/\/doi.org\/10.1186\/s13045-018-0675-4.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"561_CR16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","volume":"105","author":"RM Stone","year":"2005","unstructured":"Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105(1):54\u201360. https:\/\/doi.org\/10.1182\/blood-2004-03-0891.","journal-title":"Blood"},{"issue":"3","key":"561_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/2040620714532123","volume":"5","author":"SA Wander","year":"2014","unstructured":"Wander SA, Levis MJ, Fathi AT. The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Ther Adv Hematol. 2014;5(3):65\u201377. https:\/\/doi.org\/10.1177\/2040620714532123.","journal-title":"Ther Adv Hematol"},{"issue":"10","key":"561_CR18","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1182\/blood-2003-11-3775","volume":"103","author":"BD Smith","year":"2004","unstructured":"Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004;103(10):3669\u201376. https:\/\/doi.org\/10.1182\/blood-2003-11-3775.","journal-title":"Blood"},{"issue":"17","key":"561_CR19","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1182\/blood-2008-09-177030","volume":"113","author":"KW Pratz","year":"2009","unstructured":"Pratz KW, Cortes J, Roboz GJ, Rao N, Arowojolu O, Stine A, et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood. 2009;113(17):3938\u201346. https:\/\/doi.org\/10.1182\/blood-2008-09-177030.","journal-title":"Blood"},{"issue":"5","key":"561_CR20","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/bjh.13353","volume":"169","author":"W Fiedler","year":"2015","unstructured":"Fiedler W, Kayser S, Kebenko M, Janning M, Krauter J, Schittenhelm M, et al. A phase I\/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. Br J Haematol. 2015;169(5):694\u2013700. https:\/\/doi.org\/10.1111\/bjh.13353.","journal-title":"Br J Haematol"},{"issue":"6","key":"561_CR21","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1021\/acs.jmedchem.0c01851","volume":"64","author":"Z Wang","year":"2021","unstructured":"Wang Z, Cai J, Cheng J, Yang W, Zhu Y, Li H, et al. FLT3 inhibitors in acute myeloid leukemia: challenges and recent developments in overcoming resistance. J Med Chem. 2021;64(6):2878\u2013900. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01851.","journal-title":"J Med Chem"},{"issue":"1","key":"561_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00992-1","volume":"13","author":"MT Gebru","year":"2020","unstructured":"Gebru MT, Wang HG. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia. J Hematol Oncol. 2020;13(1):155. https:\/\/doi.org\/10.1186\/s13045-020-00992-1.","journal-title":"J Hematol Oncol"},{"issue":"26","key":"561_CR23","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","volume":"129","author":"M Levis","year":"2017","unstructured":"Levis M. Midostaurin approved for FLT3-mutated AML. Blood. 2017;129(26):3403\u20136. https:\/\/doi.org\/10.1182\/blood-2017-05-782292.","journal-title":"Blood"},{"issue":"10388","key":"561_CR24","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/s0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Zak P, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10388):1571\u201383. https:\/\/doi.org\/10.1016\/s0140-6736(23)00464-6.","journal-title":"Lancet"},{"issue":"5","key":"561_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00495-3","volume":"11","author":"N Daver","year":"2021","unstructured":"Daver N, Venugopal S, Ravandi F. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J. 2021;11(5):104. https:\/\/doi.org\/10.1038\/s41408-021-00495-3.","journal-title":"Blood Cancer J"},{"issue":"2","key":"561_CR26","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/cas.14274","volume":"111","author":"H Kiyoi","year":"2020","unstructured":"Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020;111(2):312\u201322. https:\/\/doi.org\/10.1111\/cas.14274.","journal-title":"Cancer Sci"},{"issue":"12","key":"561_CR27","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1182\/blood-2010-01-266742","volume":"117","author":"T Sato","year":"2011","unstructured":"Sato T, Yang X, Knapper S, White P, Smith BD, Galkin S, et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood. 2011;117(12):3286\u201393. https:\/\/doi.org\/10.1182\/blood-2010-01-266742.","journal-title":"Blood"},{"issue":"1","key":"561_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/bjh.12599","volume":"164","author":"X Yang","year":"2014","unstructured":"Yang X, Sexauer A, Levis M. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase. Br J Haematol. 2014;164(1):61\u201372. https:\/\/doi.org\/10.1111\/bjh.12599.","journal-title":"Br J Haematol"},{"issue":"4","key":"561_CR29","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1182\/blood-2006-05-023804","volume":"109","author":"O Piloto","year":"2007","unstructured":"Piloto O, Wright M, Brown P, Kim KT, Levis M, Small D. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood. 2007;109(4):1643\u201352. https:\/\/doi.org\/10.1182\/blood-2006-05-023804.","journal-title":"Blood"},{"issue":"22","key":"561_CR30","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.1158\/0008-5472.can-15-3569","volume":"76","author":"E Traer","year":"2016","unstructured":"Traer E, Martinez J, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, et al. FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia. Cancer Res. 2016;76(22):6471\u201382. https:\/\/doi.org\/10.1158\/0008-5472.can-15-3569.","journal-title":"Cancer Res"},{"issue":"6","key":"561_CR31","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00280-013-2287-6","volume":"72","author":"C Dutreix","year":"2013","unstructured":"Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers. Cancer Chemother Pharmacol. 2013;72(6):1223\u201334. https:\/\/doi.org\/10.1007\/s00280-013-2287-6.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7397","key":"561_CR32","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nature11016","volume":"485","author":"CC Smith","year":"2012","unstructured":"Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485(7397):260\u20133. https:\/\/doi.org\/10.1038\/nature11016.","journal-title":"Nature"},{"issue":"8","key":"561_CR33","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1158\/2159-8290.cd-18-1453","volume":"9","author":"CM McMahon","year":"2019","unstructured":"McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, et al. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 2019;9(8):1050\u201363. https:\/\/doi.org\/10.1158\/2159-8290.cd-18-1453.","journal-title":"Cancer Discov"},{"issue":"7","key":"561_CR34","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1182\/bloodadvances.2021006489","volume":"6","author":"CC Smith","year":"2022","unstructured":"Smith CC, Levis MJ, Perl AE, Hill JE, Rosales M, Bahceci E. Molecular profile of FLT3-mutated relapsed\/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144\u201355. https:\/\/doi.org\/10.1182\/bloodadvances.2021006489.","journal-title":"Blood Adv"},{"issue":"4","key":"561_CR35","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.chembiol.2005.04.004","volume":"12","author":"AA McCarthy","year":"2005","unstructured":"McCarthy AA. Exelixis: integrated drug-discovery and development platform for human therapeutics. Chem Biol. 2005;12(4):407\u20138. https:\/\/doi.org\/10.1016\/j.chembiol.2005.04.004.","journal-title":"Chem Biol"},{"issue":"11","key":"561_CR36","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1182\/blood.v110.11.2515.2515","volume":"110","author":"S Trudel","year":"2007","unstructured":"Trudel S, Yang XZ, Li ZH, Liang S-b, Aftab DT. Evaluation of XL999, a potent inhibitor of FGFR3, for the potential treatment of t (4; 14) positive multiple myeloma. Blood. 2007;110(11):2515. https:\/\/doi.org\/10.1182\/blood.v110.11.2515.2515.","journal-title":"Blood"},{"issue":"18_suppl","key":"561_CR37","doi-asserted-by":"publisher","first-page":"18112","DOI":"10.1200\/jco.2007.25.18_suppl.18112","volume":"25","author":"R March","year":"2007","unstructured":"March R, Mirtsching B, Modi S, Wertheim M. A phase II study of XL999 in patients (pts) with NSCLC. J Clin Oncol. 2007;25(18_suppl):18112. https:\/\/doi.org\/10.1200\/jco.2007.25.18_suppl.18112.","journal-title":"J Clin Oncol"},{"issue":"18_suppl","key":"561_CR38","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1200\/jco.2007.25.18_suppl.3591","volume":"25","author":"L Cripe","year":"2007","unstructured":"Cripe L, McGuire W, Wertheim M, Eisenberg P, Stadler W, Paquette R, et al. Integrated report of the phase 2 experience with XL999 administered IV to patients (pts) with NSCLC, renal cell CA (RCC), metastatic colorectal CA (CRC), recurrent ovarian CA, acute myelogenous leaukemia (AML), and multiple myeloma (MM). J Clin Oncol. 2007;25(18_suppl):3591. https:\/\/doi.org\/10.1200\/jco.2007.25.18_suppl.3591.","journal-title":"J Clin Oncol"},{"issue":"10","key":"561_CR39","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1177\/1947601910396505","volume":"1","author":"E Weisberg","year":"2010","unstructured":"Weisberg E, Roesel J, Furet P, Bold G, Imbach P, Florsheimer A, et al. Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. Genes Cancer. 2010;1(10):1021\u201332. https:\/\/doi.org\/10.1177\/1947601910396505.","journal-title":"Genes Cancer"},{"issue":"1","key":"561_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40364-022-00447-4","volume":"11","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Wang P, Wang Y, Shen Y. Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia. Biomark Res. 2023;11(1):8. https:\/\/doi.org\/10.1186\/s40364-022-00447-4.","journal-title":"Biomark Res"},{"issue":"3","key":"561_CR41","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1182\/bloodadvances.2019000919","volume":"4","author":"TC Tarver","year":"2020","unstructured":"Tarver TC, Hill JE, Rahmat L, Perl AE, Bahceci E, Mori K, et al. Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations. Blood Adv. 2020;4(3):514\u201324. https:\/\/doi.org\/10.1182\/bloodadvances.2019000919.","journal-title":"Blood Adv"},{"issue":"4","key":"561_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121177","volume":"10","author":"JA Zorn","year":"2015","unstructured":"Zorn JA, Wang Q, Fujimura E, Barros T, Kuriyan J. Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220). PLoS ONE. 2015;10(4):e0121177. https:\/\/doi.org\/10.1371\/journal.pone.0121177.","journal-title":"PLoS ONE"},{"issue":"2","key":"561_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020350","volume":"16","author":"M Santorsola","year":"2024","unstructured":"Santorsola M, Capuozzo M, Nasti G, Sabbatino F, Di Mauro A, Di Mauro G, et al. Exploring the spectrum of VEGF inhibitors\u2019 toxicities from systemic to intra-vitreal usage in medical practice. Cancers (Basel). 2024;16(2):350. https:\/\/doi.org\/10.3390\/cancers16020350.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"561_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101204","volume":"4","author":"V Subbiah","year":"2023","unstructured":"Subbiah V, Verstovsek S. Clinical development and management of adverse events associated with FGFR inhibitors. Cell Rep Med. 2023;4(10):101204. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101204.","journal-title":"Cell Rep Med"},{"issue":"14","key":"561_CR45","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1182\/blood-2013-03-491431","volume":"122","author":"I Ben-Batalla","year":"2013","unstructured":"Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, et al. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood. 2013;122(14):2443\u201352. https:\/\/doi.org\/10.1182\/blood-2013-03-491431.","journal-title":"Blood"},{"issue":"10","key":"561_CR46","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.3324\/haematol.2018.205385","volume":"104","author":"PY Dumas","year":"2019","unstructured":"Dumas PY, Naudin C, Martin-Lanneree S, Izac B, Casetti L, Mansier O, et al. Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL. Haematologica. 2019;104(10):2017\u201327. https:\/\/doi.org\/10.3324\/haematol.2018.205385.","journal-title":"Haematologica"},{"issue":"12","key":"561_CR47","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1038\/leu.2015.147","volume":"29","author":"IK Park","year":"2015","unstructured":"Park IK, Mundy-Bosse B, Whitman SP, Zhang X, Warner SL, Bearss DJ, et al. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia. Leukemia. 2015;29(12):2382\u20139. https:\/\/doi.org\/10.1038\/leu.2015.147.","journal-title":"Leukemia"},{"issue":"14","key":"561_CR48","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","volume":"114","author":"PP Zarrinkar","year":"2009","unstructured":"Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114(14):2984\u201392. https:\/\/doi.org\/10.1182\/blood-2009-05-222034.","journal-title":"Blood"},{"issue":"5","key":"561_CR49","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s10637-017-0470-z","volume":"35","author":"M Mori","year":"2017","unstructured":"Mori M, Kaneko N, Ueno Y, Yamada M, Tanaka R, Saito R, et al. Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017;35(5):556\u201365. https:\/\/doi.org\/10.1007\/s10637-017-0470-z.","journal-title":"Invest New Drugs"},{"issue":"7","key":"561_CR50","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/s1470-2045(18)30240-7","volume":"19","author":"J Cortes","year":"2018","unstructured":"Cortes J, Perl AE, Dohner H, Kantarjian H, Martinelli G, Kovacsovics T, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;19(7):889\u2013903. https:\/\/doi.org\/10.1016\/s1470-2045(18)30240-7.","journal-title":"Lancet Oncol"},{"issue":"18","key":"561_CR51","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/nejmoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728\u201340. https:\/\/doi.org\/10.1056\/nejmoa1902688.","journal-title":"N Engl J Med"},{"issue":"10","key":"561_CR52","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1038\/s41375-018-0102-4","volume":"32","author":"S Rudat","year":"2018","unstructured":"Rudat S, Pfaus A, Cheng YY, Holtmann J, Ellegast JM, Buhler C, et al. RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia. Leukemia. 2018;32(10):2189\u2013202. https:\/\/doi.org\/10.1038\/s41375-018-0102-4.","journal-title":"Leukemia"},{"issue":"17","key":"561_CR53","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1182\/blood-2011-07-365726","volume":"119","author":"H Leischner","year":"2012","unstructured":"Leischner H, Albers C, Grundler R, Razumovskaya E, Spiekermann K, Bohlander S, et al. SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML. Blood. 2012;119(17):4026\u201333. https:\/\/doi.org\/10.1182\/blood-2011-07-365726.","journal-title":"Blood"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00561-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00561-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00561-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:43:32Z","timestamp":1788504212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00561-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["561"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00561-x","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Ethics Committee of Guangzhou First People\u2019s Hospital (Approval No. K-2026\u2013124-01) in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants for cryopreservation of BM samples and their subsequent use in both in vitro and in vivo studies. All animal experiments were approved by the Animal Ethics Committee of the Greater Bay Area Institute of Precision Medicine (Guangzhou) (Approval No. IPMGBA-26\u20130014).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that no known competing financial interests or personal relationships exist that present a potential conflict of interest regarding this work.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"161"}}